Further clinical studies will answer the question as to whether 18F-ASEM, as the best molecular probe for α7nAChR reported in the literature, can be reliably applied clinically in noninvasive, early diagnosis and monitoring of the vulnerable atherosclerotic plaques of patients who would suffer from acute coronary syndrome. The gene discussed is CHRNA7; the disease is acute coronary syndrome.